A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Wang, Sheng-Min | - |
dc.contributor.author | Bahk, Won-Myong | - |
dc.contributor.author | Lee, Soo-Jung | - |
dc.contributor.author | Patkar, Ashwin A. | - |
dc.contributor.author | Masand, Prakash S. | - |
dc.contributor.author | Mandelli, Laura | - |
dc.contributor.author | Pae, Chi-Un | - |
dc.contributor.author | Serretti, Alessandro | - |
dc.date.accessioned | 2021-09-02T04:20:19Z | - |
dc.date.available | 2021-09-02T04:20:19Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-11 | - |
dc.identifier.issn | 1738-1088 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/72029 | - |
dc.description.abstract | Objective: Pharmacogenomic-based antidepressant treatment (PGATx) may result in more precise pharmacotherapy of major depressive disorder (MDD) with better drug therapy guidance. Methods: An 8-week, randomized, single-blind clinical trial was conducted to evaluate the effectiveness and tolerability of PGATx in 100 patients with MDD. All recruited patients were randomly allocated either to PGATx (n=52) or treatment as usual (TAU, n=48) groups. The primary endpoint was a change of total score of the Hamilton Depression Rating Scale-17 (HAMD-17) from baseline to end of treatment. Response rate (at least 50% reduction in HAMD-17 score from baseline), remission rate (HAMD-17 score <= 7 at the end of treatment) as well as the change of total score of Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER) from baseline to end of treatment were also investi gated. Results: The mean change of HAMD-17 score was significantly different between two groups favoring PGATx by -4.1 point of difference (p=0.010) at the end of treatment. The mean change in the FIBSER score from baseline was significantly different between two treatment groups favoring PGATx by -2.5 point of difference (p=0.028). The response rate (71.7 % vs. 43.6%, p=0.014) were also significantly higher in PGATx than in TAU at the end of treatment, while the remission rate was numerically higher in PGATx than in TAU groups without statistical difference (45.5% vs. 25.6%, p=0.071). The reason for early drop-out associated with adverse events was also numerically higher in TAU (n=9, 50.0%) than in PGATx (n=4, 30.8%). Conclusion: The present study clearly demonstrate that PGATx may be a better treatment option in the treatment of MDD in terms of effectiveness and tolerability; however, study shortcomings may limit a generalization. Adequately-powered, well-designed, subsequent studies should be mandatory to prove its practicability and clinical utility for routine practice. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN COLL NEUROPSYCHOPHARMACOLOGY | - |
dc.subject | COST-EFFECTIVENESS | - |
dc.subject | GUIDED TREATMENT | - |
dc.subject | TERM OUTCOMES | - |
dc.subject | GUIDELINES | - |
dc.subject | METAANALYSIS | - |
dc.subject | INFORMATION | - |
dc.subject | MEDICATIONS | - |
dc.subject | UTILITY | - |
dc.subject | ASSOCIATION | - |
dc.subject | PSYCHIATRY | - |
dc.title | A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.identifier.doi | 10.9758/cpn.2018.16.4.469 | - |
dc.identifier.scopusid | 2-s2.0-85055782437 | - |
dc.identifier.wosid | 000448050400012 | - |
dc.identifier.bibliographicCitation | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, v.16, no.4, pp.469 - + | - |
dc.relation.isPartOf | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE | - |
dc.citation.title | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE | - |
dc.citation.volume | 16 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 469 | - |
dc.citation.endPage | + | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | COST-EFFECTIVENESS | - |
dc.subject.keywordPlus | GUIDED TREATMENT | - |
dc.subject.keywordPlus | TERM OUTCOMES | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | INFORMATION | - |
dc.subject.keywordPlus | MEDICATIONS | - |
dc.subject.keywordPlus | UTILITY | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | PSYCHIATRY | - |
dc.subject.keywordAuthor | Depressive disorder | - |
dc.subject.keywordAuthor | Pharmacogenetic testing | - |
dc.subject.keywordAuthor | Antidepressants | - |
dc.subject.keywordAuthor | Precision medicine | - |
dc.subject.keywordAuthor | Effects | - |
dc.subject.keywordAuthor | Tolerance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.